In recent years, nanoparticles have evolved to a clinical modality to deliver diverse nucleic
acids. Rising interest in nanomedicines comes from proven safety and efficacy profiles …

The treatment of women's health-related conditions, including reproductive tract and
pregnancy disorders, faces distinct challenges and microenvironments, such as the vaginal …

Ionizable lipid nanoparticles (LNPs) are the most clinically advanced nonviral platform for
mRNA delivery. While they have been explored for applications including vaccines and …

Treating pregnancy-related disorders is exceptionally challenging because the threat of
maternal and/or fetal toxicity discourages the use of existing medications and hinders new …

During healthy pregnancy, the placenta develops to allow for exchange of nutrients and
oxygen between the mother and the fetus. However, placental dysregulation can lead to …

The successful development of nonviral delivery systems for nucleic acids has been
reported extensively over the past years. Increasingly employed to improve the delivery …

Female reproductive health has traditionally been an underrepresented area of research in
the drug delivery sciences. This disparity is also seen in the emerging field of mRNA …

RNA therapeutics, such as mRNA, siRNA, and CRISPR–Cas9, present exciting avenues for
treating diverse diseases. However, their potential is commonly hindered by vulnerability to …

Autoimmune disorders have risen to be among the most prevalent chronic diseases across
the globe, affecting approximately 5–7% of the population. As autoimmune diseases steadily …

At the onset of pregnancy, people with preexisting conditions face additional challenges in
carrying their pregnancy to term, as the safety of the developing fetus and pregnant person …